The action of a novel fluoroquinolone antibiotic agent antofloxacin hydrochloride on human-ether-à-go-go-related gene potassium channel

Basic and Clinical Pharmacology and Toxicology

Volumn 107, Issue 2, 2010, Pages 643-649

  Guo, Jia ^a   Han, Sheng Na ^c   Liu, Jin Xu ^a   Zhang, Xiang Mei ^a   Hu, Zhen Sheng ^a   Shi, Jie ^a   Zhang, Li Rong ^c   Zhao, Zhong Zhong ^a   Zhang, Zhao ^a,b  

^a College of Life Science Jiangsu Key Laboratory for Molecular and Medical Biotechnology ^*  (China)

^b NANJING NORMAL UNIVERSITY   (China)

^c ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTOFLOXACIN HYDROCHLORIDE; LEVOFLOXACIN; POTASSIUM CHANNEL HERG; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTOFLOXACIN; ERG1 POTASSIUM CHANNEL; OFLOXACIN; POTASSIUM CHANNEL BLOCKING AGENT; QUINOLONE DERIVATIVE; VOLTAGE GATED POTASSIUM CHANNEL;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ELECTRIC POTENTIAL; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; VOLTAGE CLAMP; WHOLE CELL; ANALOGS AND DERIVATIVES; CELL LINE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; EMBRYOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; KIDNEY; METABOLISM; PATCH CLAMP TECHNIQUE; PROTEIN TRANSPORT; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; FLUOROQUINOLONES; GENE EXPRESSION REGULATION; HUMANS; KIDNEY; LEVOFLOXACIN; OFLOXACIN; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED; PROTEIN TRANSPORT; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 77954714811     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00550.x     Document Type: Article

References (23)

1. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006 440 : 463 469.
2. + channels and drug-acquired long QT syndrome. Therapie 2000 55 : 185 193.
3. Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH. The cardiac pharmacodynamics of therapeutic doses of sparfloxacin. Clin Ther 1999 21 : 1171 1181. (Pubitemid 29380472)
4. Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH. The effect of terfenadine on the cardiac pharmacodynamics of sparfloxacin. Clin Ther 1999 21 : 1514 1524. (Pubitemid 29449552)
5. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999 28 : 352 364.
6. Takahara A, Sugiyama A, Satoh Y, Iwasaki H, Nakamura Y, Hashimoto K. Cardiovascular profile of the canine torsades de pointes arrhythmia model assessed by echocardiographic and haemodynamic methods. Basic Clin Pharmacol Toxicol 2007 101 : 35 40.
7. Thomsen MB, Volders PG, Beekman JD, Matz J, Vos MA. Beat-to-Beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes. J Am Coll Cardiol 2006 48 : 1268 1276.
8. Xiao Y, Lu Y, Kang Z, Hou F, Wang S, Li T et al. Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. Int J Clin Pharmacol Ther 2008 46 : 172 179. (Pubitemid 351493987)
9. Xiao Y, Lu Y, Kang Z, Zhang M, Liu Y, Zhang M et al. Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. Biopharm Drug Dispos 2008 29 : 167 172. (Pubitemid 351722161)
10. Yap YG, Camm J. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation. BMJ 2000 320 : 1158 1159.
11. Shang SY, Han SN, Jing Y, Cheng SM, Qiao P, Zhang Z. Prolongation of cardiac action potential duration induced by antofloxacin in isolated guinea pig papillary muscles. Bas Clin Med 2008 28 : 752 755. (Abstract in English).
12. Bischoff U, Schmidt C, Netzer R, Pongs O. Effects of fluoroquinolones on HERG currents. Eur J Pharmacol 2000 406 : 341 343.
13. + channel HERG. Mol Pharmacol 2001 59 : 122 126.
14. + channels. Toxicology 2006 228 : 239 248.
15. + channel blockade by the fluoroquinolone antibiotic moxifloxacin. Br J Pharmacol 2006 147 : 905 916.
16. Duncan RS, McPate MJ, Ridley JM, Gao Z, James AF, Leishman DJ et al. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem Pharmacol 2007 74 : 425 437.
17. Gargallo-Viola D, Ferrer S, Tudela E, Robert M, Coll R, Roser R et al. Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. Antimicrob Agents Chemother 2001 45 : 3113 3121.
18. Gargallo-Viola D, Esteve M, Moros M, Coll R, Xicota MA, de Andres C et al. Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent. Antimicrob Agents Chemother 1990 34 : 2318 2326.
19. Pang XY, Liu L, Zhang DM, Wang GJ, Xie L, Liu XD. The pharmacokinetics of antofloxacin in renally impaired rats. J Pharm Pharmacol 2008 60 : 667 670.
20. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003 58 : 32 45.
21. Zebedin V, Koenig X, Radenkovic M, Pankevych H, Todt H, Freissmuth M et al. Effects of duramycin on cardiac voltage-gated ion channels. Naunyn Schmiedeberg's Arch Pharmacol 2008 377 : 87 100.
22. Lu HR, Vlaminckx E, Van de Water A, Rohrbacher J, Hermans A, Gallacher DJ. In vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur J Pharmacol 2007 577 : 222 232.
23. Wang D, Patel C, Cui C, Yan GX. Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation. Pharmacol Ther 2008 119 : 141 151.